NEW YORK, Feb. 20, 2013 /PRNewswire-USNewswire/ --The Michael J. Fox Foundation (MJFF) is today announcing the launch of four new funding programs focused on driving forward research toward transformative treatments and a cure for Parkinson's disease (PD). MJFF places a strong emphasis on translational and clinical research, but also supports high-risk/high-reward discovery work to help keep new ideas flowing into the drug development pipeline.
The new funding opportunities are open to both academic and industry researchers. Projects should promote PD drug development around the most promising therapeutic pathways and targets, including leading genetic targets alpha-synuclein and LRRK2.
Researchers can also apply for access to MJFF's growing inventory of tissue samples from pre-clinical models and clinical populations for projects seeking to address promising Parkinson's ideas.
In addition to the four launching programs, four other rolling programs are currently open and accepting applications. Check out the complete list and apply for funding at https://www.michaeljfox.org/research/apply-for-grant.html.
Brief descriptions of the launching programs follow.
MJFF Biosample and Tissue Resource RFA - Fall 2013
MJFF has supported several pre-clinical and clinical efforts to generate valuable biospecimen tissue resources for the research community. This is an opportunity for researchers to apply to use these samples.
Informational Conference Call: March 6, 2013 at 12pm US EST
Pre-Proposals Due: April 3, 2013
To participate in the call and receive call-in details, please RSVP via email toconferencecalls@michaeljfox.org.
LRRK2 Pharmacodynamic Assays 2013
MJFF seeks to support projects to identify, generate and validate measures and assays of the function of the protein leucine-rich repeat kinase 2 (LRRK2) that accelerate development and testing of LRRK2-targeted therapies for PD. Successful applicants will be granted membership in the MJFF LRRK2 Consortium, where they can share information, data and resources with awardees of this and other LRRK2-related efforts.
Informational Conference Call: March 5, 2013 at 12pm US EST
Pre-Proposals Due: April 3, 2013
To participate in the call and receive call-in details, please RSVP via email toconferencecalls@michaeljfox.org.
Therapeutic Pipeline Program - Fall 2013
The goal of theTherapeutic Pipeline Programis to support therapeutic development around targets within pathways that have been implicated in altering the course of PD. Proposals may seek support of key steps along the entire therapeutic pipeline, including therapeutic screening, identification and optimization, pre-clinicalin vivotesting and clinical testing.
Applicants are asked to develop a clear plan, including major 'go/no go' decision milestones, for moving a therapeutic strategy toward clinical utility in people with PD. Investigators new to PD research are encouraged to collaborate with experienced PD scientists and/or companies to ensure the greatest chance for success.
Informational Conference Call: March 7, 2013 at 12pm US EST
Pre-Proposals Due: April 3, 2013
To participate in the call and receive call-in details, please RSVP via email toconferencecalls@michaeljfox.org.
Synuclein Therapeutic Acceleration Program (SynTAP 2013)
MJFF seeks to aggressively move therapeutic compounds and biologics targeting alpha-synuclein into clinical testing by funding mid to late-stage pre-clinical development work. Studies should be designed to obtain data required for Investigational New Drug application submission, and for future clinical testing of the therapeutic.
Informational Conference Call: March 13, 2013 at 12pm US EDT
Pre-Proposals Due: April 3, 2013
To participate in the call and receive call-in details, please RSVP via email toconferencecalls@michaeljfox.org.
About The Michael J. Fox Foundation for Parkinson's Research
As the world's largest private funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today.The Foundationpursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $300 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world.
For more information, visit us at:
Web site:michaeljfox.org
Facebook:facebook.com/michaeljfoxfoundation
LinkedIn:bit.ly/mjffPDOR
Twitter: @MichaelJFoxOrg
SOURCE The Michael J. Fox Foundation
